0HX7.LSE Adicet Bio, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-69.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0HX7.LSE undervalued?

Graham number

The Graham number of Adicet Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adicet Bio, Inc. fundamental analysis

No fundamental analysis for Adicet Bio, Inc. yet.

Adicet Bio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-spec…

Full company profile